A Multicenter, Prospective Phase II Clinical Study of Tislelizumab in Combination With Chemotherapy for the Perioperative Treatment of Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Tislelizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 23 Apr 2024 New trial record